Emergent BioSolutions | EBS - Stammkapital





Stammkapital Veränderung Datum
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Akebia Therapeutics USD 265.42M 199K 2025-12
ALKERMES USD 165.61M 503K 2025-12
Alnylam Pharmaceuticals USD 132.38M 585K 2025-12
Amarin USD 20.81M 13K 2025-12
ANI Pharmaceuticals USD 22.49M 760K 2025-12
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Coherus Biosciences USD 121.16M 4.92M 2025-12
Emergent BioSolutions USD 100K 0 2023-06
Exelixis USD 268.1M 2.03M 2025-09
Glaxosmithkline GBP 4.08B 49.43M 2025-12
Heron Therapeutics USD 188.31M 4.99M 2025-12
Ionis Pharmaceuticals USD 161.97M 836K 2025-12
Ironwood Pharmaceuticals USD 160K 0 2024-12
Lexicon Pharmaceuticals USD 363.47M 67K 2025-12
Lonza CHF 68.64M 0 2025-12
Merck USD 2.49B 15.79M 2025-09
Moderna USD 391M 2M 2025-09
Myriad Genetics USD 93.5M 400K 2025-12
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.1M 400K 2025-12
Pacira USD 41.12M 1.85M 2025-12
Pfizer USD 5.69B 1000K 2025-09
PTC Therapeutics USD 81.47M 1.54M 2025-12
Sanofi EUR 1.21B 8.25M 2026-03
Sarepta Therapeutics USD 104.96M 196K 2025-12
United Therapeutics USD 43.64M 740K 2025-12
Vanda Pharmaceuticals USD 58K 0 2024-12
Xoma USD 87K 1000 2024-06